Rubius Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
Rubius Therapeutics (Nasdaq:RUBY) announces that CEO Pablo J. Cagnoni will present at the 39th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rubius Therapeutics (Nasdaq:RUBY) announces that CEO Pablo J. Cagnoni will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 8:20 a.m. ET. The presentation will showcase Rubius' innovative work in developing Red Cell Therapeutics™, a new class of medicines aimed at treating cancer and autoimmune diseases using the proprietary RED PLATFORM®. A live audio webcast will be available on the company’s website, with an archived replay accessible for 90 days.
Details
News Market Reaction – RUBY
The recorded move for RUBY in the trading session of this news was +1.58%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, announced today that Pablo J. Cagnoni, M.D., president and chief executive officer, will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021, at 8:20 a.m. ET.
A live audio webcast will be available within the Investors & Media section of the Rubius Therapeutics website. An archived replay will be accessible for 90 days following the event.
About Rubius Therapeutics
Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Rubius Therapeutics was recently named among the Top Places to Work in Massachusetts by the Boston Globe, and its manufacturing site was recently named 2020 Top 5 Best Places to Work in Rhode Island among medium-sized companies by Providence Business News. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook.
Contacts:
Investors
Elhan Webb, CFA, Head of Investor Relations
elhan.webb@rubiustx.com
Media
Marissa Hanify, Director, Corporate Communications
Marissa.hanify@rubiustx.com
Dan Budwick, 1AB
+1 (973) 271-6085
dan@1abmedia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.